Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety
Two series of olmutinib derivatives containing an acrylamide moiety were designed and synthesized, and their IC<sub>50</sub> values against cancer cell lines (A549, H1975, NCI-H460, LO2, and MCF-7) were evaluated. Most of the compounds exhibited moderate cytotoxic activity against the fi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/26/10/3041 |
| _version_ | 1797533412306714624 |
|---|---|
| author | Xiaohan Hu Sheng Tang Feiyi Yang Pengwu Zheng Shan Xu Qingshan Pan Wufu Zhu |
| author_facet | Xiaohan Hu Sheng Tang Feiyi Yang Pengwu Zheng Shan Xu Qingshan Pan Wufu Zhu |
| author_sort | Xiaohan Hu |
| collection | DOAJ |
| description | Two series of olmutinib derivatives containing an acrylamide moiety were designed and synthesized, and their IC<sub>50</sub> values against cancer cell lines (A549, H1975, NCI-H460, LO2, and MCF-7) were evaluated. Most of the compounds exhibited moderate cytotoxic activity against the five cancer cell lines. The most promising compound, <b>H10</b>, showed not only excellent activity against EGFR kinase but also positive biological activity against PI3K kinase. The structure–activity relationship (SAR) suggested that the introduction of dimethylamine scaffolds with smaller spatial structures was more favorable for antitumor activity. Additionally, the substitution of different acrylamide side chains had different effects on the activity of compounds. Generally, compounds <b>H7</b> and <b>H10</b> were confirmed as promising antitumor agents. |
| first_indexed | 2024-03-10T11:15:13Z |
| format | Article |
| id | doaj.art-734fc3db807747daa4f7d4c019369723 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T11:15:13Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-734fc3db807747daa4f7d4c0193697232023-11-21T20:30:22ZengMDPI AGMolecules1420-30492021-05-012610304110.3390/molecules26103041Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide MoietyXiaohan Hu0Sheng Tang1Feiyi Yang2Pengwu Zheng3Shan Xu4Qingshan Pan5Wufu Zhu6School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, ChinaSchool of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, ChinaSchool of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, ChinaSchool of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, ChinaSchool of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, ChinaSchool of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, ChinaSchool of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, ChinaTwo series of olmutinib derivatives containing an acrylamide moiety were designed and synthesized, and their IC<sub>50</sub> values against cancer cell lines (A549, H1975, NCI-H460, LO2, and MCF-7) were evaluated. Most of the compounds exhibited moderate cytotoxic activity against the five cancer cell lines. The most promising compound, <b>H10</b>, showed not only excellent activity against EGFR kinase but also positive biological activity against PI3K kinase. The structure–activity relationship (SAR) suggested that the introduction of dimethylamine scaffolds with smaller spatial structures was more favorable for antitumor activity. Additionally, the substitution of different acrylamide side chains had different effects on the activity of compounds. Generally, compounds <b>H7</b> and <b>H10</b> were confirmed as promising antitumor agents.https://www.mdpi.com/1420-3049/26/10/3041acrylamideolmutinib derivativesEGFRinhibitor |
| spellingShingle | Xiaohan Hu Sheng Tang Feiyi Yang Pengwu Zheng Shan Xu Qingshan Pan Wufu Zhu Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety Molecules acrylamide olmutinib derivatives EGFR inhibitor |
| title | Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety |
| title_full | Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety |
| title_fullStr | Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety |
| title_full_unstemmed | Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety |
| title_short | Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety |
| title_sort | design synthesis and antitumor activity of olmutinib derivatives containing acrylamide moiety |
| topic | acrylamide olmutinib derivatives EGFR inhibitor |
| url | https://www.mdpi.com/1420-3049/26/10/3041 |
| work_keys_str_mv | AT xiaohanhu designsynthesisandantitumoractivityofolmutinibderivativescontainingacrylamidemoiety AT shengtang designsynthesisandantitumoractivityofolmutinibderivativescontainingacrylamidemoiety AT feiyiyang designsynthesisandantitumoractivityofolmutinibderivativescontainingacrylamidemoiety AT pengwuzheng designsynthesisandantitumoractivityofolmutinibderivativescontainingacrylamidemoiety AT shanxu designsynthesisandantitumoractivityofolmutinibderivativescontainingacrylamidemoiety AT qingshanpan designsynthesisandantitumoractivityofolmutinibderivativescontainingacrylamidemoiety AT wufuzhu designsynthesisandantitumoractivityofolmutinibderivativescontainingacrylamidemoiety |